Seizert Capital Partners, LLC Alkermes Plc. Transaction History

Seizert Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 30, 2023	BUY	$21.94 - $26.24 $14,129 - $16,898	644 Added 0.24%	267,776 $7 Million
Q3 2022 Nov 02, 2022	SELL	$22.0 - $31.87 $5,544 - $8,031	-252 Reduced 0.09%	267,132 $5.97 Million
Q2 2022 Aug 04, 2022	SELL	$26.4 - $30.54 $39,547 - $45,748	-1,498 Reduced 0.56%	267,384 $7.97 Million
Q1 2022 May 03, 2022	SELL	$23.07 - $27.99 $297,856 - $361,378	-12,911 Reduced 4.58%	268,882 $7.07 Million
Q4 2021 Feb 08, 2022	SELL	$21.47 - $32.08 $1.04 Million - $1.55 Million	-48,247 Reduced 14.62%	281,793 $6.56 Million
Q3 2021 Nov 03, 2021	SELL	$23.37 - $32.13 $2.45 Million - $3.37 Million	-104,991 Reduced 24.13%	330,040 $10.2 Million
Q2 2021 Aug 05, 2021	SELL	$18.78 - $25.15 $536,525 - $718,510	-28,569 Reduced 6.16%	435,031 $10.7 Million
Q1 2021 May 05, 2021	BUY	$18.21 - $23.2 $8.44 Million - $10.8 Million	463,600 New	463,600 $8.66 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.9B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Seizert Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Seizert Capital Partners, LLC with notifications on news.